Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 14/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.57 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4493006 | 0.81 | CNR1 (0.64) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 | |
| SCHEMBL4469608 | 0.81 | CNR1 (0.72) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 | |
| SCHEMBL6100004 | 0.80 | CNR1 (0.64) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 | |
| SCHEMBL6102255 | 0.80 | CNR1 (0.64) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 | |
| SCHEMBL4492938 | 0.79 | CNR1 (0.75) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 | |
| SCHEMBL4798385 | 0.78 | CNR1 (1.00) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 | |
| SCHEMBL4838798 | 0.77 | CNR1 (0.69) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 | |
| SCHEMBL13135006 | 0.77 | CNR1 (1.00) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL14211072 | 0.76 | CNR1 (1.00) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 | |
| SCHEMBL4491833 | 0.74 | CNR1 (0.52) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287342-A1 | Triazolopyrimidine heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287342-A1 | Triazolopyrimidine heterocycles as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | CNR1 1/4885CYP2C9 231/4885CYP2C19 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.